Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by OttawaPeteron Jan 17, 2023 1:39pm
67 Views
Post# 35228547

RE:RE:RE:Only a corporate suit could call this merger a synergy...

RE:RE:RE:Only a corporate suit could call this merger a synergy...

I am also a firm NO vote. 

RE: "Does anyone know of a proposed merger of 2 "Clinical Stage" Biotechs that has failed to materialize in recent times, upon being given full approval by the CEOs of both Biotechs?"

JD, please correct me if I am wrong, but Bioasis is technically still a pre-clinical stage company. While some partners may have used the xB3 tech in clinic, Bioasis has yet to enter the clinic with it's own investigational compounds that are -or were- in the pipeline. 

 

<< Previous
Bullboard Posts
Next >>